Implication of a rare variant in OPA1 in Cardiac Pathophysiology: From Cristae Remodelling to Contractile Dysfunction
Abstract Optic Atrophy 1 (OPA1), an important inner mitochondrial membrane GTPase, regulates mitochondrial fusion, maintains cristae structure, calcium buffering, cellular bioenergetics, preserves mtDNA and controls apoptosis. Here we examined the role of OPA1 variants in DCM using whole-exome sequencing (WES) of 5 familial and 10 sporadic DCM cases. A rare de novo OPA1 variant, c.563C>T…
A rare, newly discovered variant in the OPA1 gene has been linked to a specific type of heart disease known as Dilated Cardiomyopathy (DCM). This variant, a de novo mutation, was found in a patient with DCM but not in over 200 individuals without the condition. The OPA1 gene plays a crucial role in maintaining mitochondrial function, which is essential for heart health.
The mutation leads to structural distortion of the mutated protein, making it more likely to be broken down by the cell. This results in damaged mitochondria, reduced ATP production, and increased calcium and reactive oxygen species levels. Consequently, there is impaired mitochondrial function, decreased energy generation, and heightened susceptibility to cell death.
These findings suggest that targeting mitochondrial dysfunction via the OPA1 pathway could offer a new therapeutic strategy for managing DCM.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
